AOSLO-Based Precise Measurement of Retinal Hemodynamics: Development and Application Assessment (NCT07051317) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
AOSLO-Based Precise Measurement of Retinal Hemodynamics: Development and Application Assessment
120 participantsStarted 2025-06-25
Plain-language summary
Changes in retinal hemodynamics play a key role in the development of various eye diseases. Currently, mainstream hemodynamic evaluation techniques have low resolution and poor measurement accuracy, limiting their widespread application. Adaptive optical laser scanning ophthalmoscopy (AO-SLO) can capture retinal vascular images at the cellular level, offering the potential for high-precision retinal hemodynamic evaluation. This project will: â‘ innovate the AO-SLO blood flow imaging scanning module and acquisition mode, develop algorithms for extracting spatiotemporal signal features from blood flow images, and achieve quantitative analysis of retinal hemodynamics based on AO-SLO; â‘¡ construct an in vitro retinal hemodynamic measurement simulation eye, conduct multidimensional AO-SLO hemodynamic measurements, and establish an intelligent model for precise calibration of retinal hemodynamic parameters; â‘¢ conduct AO-SLO-based retinal hemodynamic studies in high myopia, integrating multi-modal ophthalmic imaging to investigate the patterns of changes in retinal vascular structure and blood flow function in high myopia. Ultimately, a new precision measurement imaging technology platform for retinal hemodynamics will be established.
Who can participate
Age range18 Years – 30 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants must understand the clinical study and voluntarily participate, and sign an informed consent form;
✓. Age 18-30 years old, no gender restrictions;
✓. Equivalent spherical power≤0D cylindrical power -2.0D to +2.0D, best-corrected visual acuity ≥ 1.0
Exclusion criteria
✕. Participants with significant refractive media opacity-related conditions (severe cataracts, vitreous diseases, corneal diseases, etc.) at screening, or unable to complete or cooperate with routine ophthalmic examinations;
✕. History of or concurrent conditions such as ptosis, nystagmus, diabetic retinopathy, various macular degeneration, retinal vascular diseases, optic nerve inflammatory diseases, primary angle-closure glaucoma, various secondary glaucoma, amblyopia, or severe strabismus
✕. History of previous eye surgery
✕. Patients with severe hypertension, diabetes, or other systemic diseases that cause secondary changes in the retina
✕. Patients with posterior scleral staphyloma, lacquer cracks, choroidal neovascularization, or Fuchs' spots
What they're measuring
1
Blood flow velocity in the central arteries and veins of the retina
Timeframe: 7 days after the enrollment
2
The structure of central retinal arteries and veins
Timeframe: 7 days after the enrollment
3
Retinal and choroidal capillary morphological parameters
Timeframe: 7 days after the enrollment
Trial details
NCT IDNCT07051317
SponsorZhongshan Ophthalmic Center, Sun Yat-sen University